13058-73-6

Basic information

• Product Name: 7-Nitroisoquinoline
• Synonyms: 7-Nitroisoquinoline
• CAS NO: 13058-73-6
• Molecular Formula: C₉H₆N₂O₂
• Molecular Weight: 174.16
• EINECS: -0
• Mol File: 13058-73-6.mol

Chemical Properties

• Melting Point: 177-178 °C
• Boiling Point: 353.325 °C at 760 mmHg
• Flash Point: 167.485 °C
• Appearance: /
• Density: 1.354
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.682
• PKA: 3.61±0.10(Predicted)
• CAS DataBase Reference: 7-Nitroisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Nitroisoquinoline(13058-73-6)
• EPA Substance Registry System: 7-Nitroisoquinoline(13058-73-6)

Safety Data

• Hazardous Substances Data: 13058-73-6(Hazardous Substances Data)

Usage

Uses

Used in Fluorescent Dyes:
7-nitroisoquinoline is used as a fluorescent dye for its strong fluorescent properties, which are instrumental in various applications such as biological imaging and staining. Its ability to emit light upon excitation makes it a preferred choice for visualizing and tracking biological processes at the cellular level.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 7-nitroisoquinoline is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Organic Materials:
7-nitroisoquinoline is also employed in the synthesis of organic materials, where its fluorescent characteristics contribute to the creation of advanced materials with specific optical and electronic properties.
Used in Organic Light-Emitting Diodes (OLEDs):
7-nitroisoquinoline has been studied for its potential use in OLEDs due to its strong fluorescent properties. Its application in this field could lead to the development of more efficient and longer-lasting light-emitting devices for various display and lighting technologies.

InChI:InChI=1/C9H6N2O2/c12-11(13)9-2-1-7-3-4-10-6-8(7)5-9/h1-6H

Upstream product

• 42923-79-5 7-nitro-1,2,3,4-tetrahydroisoquinoline 
• 3230-65-7 3,4-dihydroisoquinoline 
• 91-17-8 decalin 
• 99365-63-6 1-(7-nitro-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one 
• 14028-67-2 N-acetyl-1,2,3,4-tetrahydroisoquinoline 
• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 41734-55-8 5-nitro-1H-indene 
• 90033-82-2 7-Nitro-3,4-dihydroisoquinoline N-oxide 
• 99365-69-2 7-nitro-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 62541-59-7 7-nitro-3,4-dihydroisoquinoline 

Downstream Products

• 14097-35-9 2-methyl-7-nitro-1,2,3,4-tetrahydroisoquinoline 
• 1246851-57-9 7-nitro-1-(p-tolyl)isoquinoline 
• 1425782-76-8 N-(4-isopropyl-3-methylphenyl)-2-(isoquinolin-7-ylamino)nicotinamide 
• 875002-69-0 N-(4-isopropyl-3-methylphenyl)-2-(isoquinolin-7-ylamino)nicotinamide 
• 1265967-24-5 C₁₇H₁₄F₃N₃ 
• 943960-88-1 7-benzylamino-1-isoquinolinamine 
• 244219-96-3 1,7-isoquinolinediamine 
• 244219-94-1 1-chloro-7-nitro-isoquinoline 
• 943960-92-7 7-(3',4'-dichlorobenzylamino)-1-isoquinolinamine 
• 943960-91-6 7-(3'-bromobenzylamino)-1-isoquinolinamine 
• 943960-90-5 7-(4'-chlorobenzylamino)-1-isoquinolinamine 
• 943960-89-2 7-(3'-chlorobenzylamino)-1-isoquinolinamine 
• 23707-37-1 7-aminoisoquinoline 

Relevant articles and documents

Development of versatile and potent monoquaternary reactivators of acetylcholinesterase

To date, the only treatments developed for poisoning by organophosphorus compounds, the most toxic chemical weapons of mass destruction, have exhibited limited efficacy and versatility. The available causal antidotes are based on reactivation of the enzyme acetylcholinesterase (AChE), which is rapidly and pseudo-irreversibly inhibited by these agents. In this study, we developed a novel series of monoquaternary reactivators combining permanently charged moieties tethered to position 6- of 3-hydroxypyridine-2-aldoxime reactivating subunit. Highlighted representatives (21, 24, and 27; also coded as K1371, K1374, and K1375, respectively) that contained 1-phenylisoquinolinium, 7-amino-1-phenylisoquinolinium and 4-carbamoylpyridinium moieties?as peripheral anionic site ligands, respectively, showed efficacy superior or comparable to that of the clinically used standards. More importantly, these reactivators exhibited wide-spectrum efficacy and were minutely investigated via determination of their reactivation kinetics in parallel with molecular dynamics simulations to study their mechanisms of reactivation of the tabun-inhibited AChE conjugate. To further confirm the potential applicability of these candidates, a mouse in vivo assay was conducted. While K1375 had the lowest acute toxicity and the most suitable pharmacokinetic profile, the oxime K1374 with delayed elimination half-life was the most effective in ameliorating the signs of tabun toxicity. Moreover, both in vitro and in vivo, the versatility of the agents was substantially superior to that of clinically used standards. Their high efficacy and broad-spectrum capability make K1374 and K1375 promising candidates that should be further investigated for their potential as nerve agents and insecticide antidotes.

Construction of key building blocks towards the synthesis of cortistatins

This work reports the construction of key building blocks towards the synthesis of cortistatins; a family of steroidal alkaloids. Cortistatin A, being a primary target due to its superior biological properties over other congeners, has been prepared by two different synthetic routes. Synthesis of the precursor to the heavily substituted A-ring starting from d-glucose and construction of the DE-ring junction employing a Hajos-Parrish ketone as a chiral pool have been demonstrated. Efforts are underway to assemble these key fragments and build towards the total synthesis of cortistatin A.

Dehydrogenation of Nitrogen Heterocycles Using Graphene Oxide as a Versatile Metal-Free Catalyst under Air

Graphene oxide (GO) has been developed as an inexpensive, environmental friendly, metal-free carbocatalyst for the dehydrogenation of nitrogen heterocycles. Valuable compounds, such as quinoline, 3,4-dihydroisoquinoline, quinazoline, and indole derivatives, have been successfully used as substrates. The investigation of various oxygen-containing molecules with different conjugated systems indicated that both the oxygen-containing groups and large π-conjugated system in GO sheets are essential for this reaction. (Figure presented.).

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

Development of a scalable synthesis of a VEGFR inhibitor

Process development and salt selection for a novel VEGFR inhibitor are described. The overall convergent synthesis involved coupling of three key fragments, 2-chloronicotinoyl chloride, 4-isopropyl-3-methylaniline and 7-aminoisoquinoline. A cost-effective

In vitro efficacy of 7-benzylamino-1-isoquinolinamines against Plasmodium falciparum related to the efficacy of chalcones

A series of 1,7-diaminoisoquinolinamines, that are expected to mediate antimalarial activity by the same mechanism employed by the chalcones, were produced. Six 7-benzylamino-1-isoquinolinamines were found to be submicromolar inhibitors in vitro of drug-r

Scalable synthesis of cortistatin A and related structures

Full details are provided for an improved synthesis of cortistatin A and related structures as well as the underlying logic and evolution of strategy. The highly functionalized cortistatin A-ring embedded with a key heteroadamantane was synthesized by a simple and scalable five-step sequence. A chemoselective, tandem geminal dihalogenation of an unactivated methyl group, a reductive fragmentation/trapping/elimination of a bromocyclopropane, and a facile chemoselective etherification reaction afforded the cortistatin A core, dubbed "cortistatinone". A selective δ16-alkene reduction with Raney Ni provided cortistatin A. With this scalable and practical route, copious quantities of cortistatinone, δ16-cortistatin A (the equipotent direct precursor to cortistatin A), and its related analogues were prepared for further biological studies.

Luminescent bimetallic lanthanide bioprobes for cellular imaging with excitation in the visible-light range

A series of homoditopic ligands H2LCX (X=4-6) has been designed to self-assemble with lanthanide ions (LnIII), resulting in neutral bimetallic helicates of overall composition [Ln 2(LCX)3] with the aim of testing the influence of substituents on the photophysical properties, particularly the excitation wavelength. The complex species are thermodynamically stable in water (logβ23 in the range 26-28 at pH 7.4) and display a metal-ion environment with pseudo-D3 symmetry and devoid of coordinated water molecules. The emission of EuIII, TbIII and Yb III is sensitised to various extents, depending on the properties of the ligand donor levels. The best helicate is [Eu2(L C5)3] with excitation maxima at 350 and 365 nm and a quantum yield of 9%. The viability of cervix cancer HeLa cells is unaffected when incubated with up to 500 μm of the chelate during 24 h. The helicate permeates into the cells by endocytosis and locates into lysosomes, which co-localise with the endoplasmatic reticulum, as demonstrated by counterstaining experiments. The relatively long excitation wavelength allows easy recording of bright luminescent images on a confocal microscope (μcxc = 405 nm). The new lanthanide bioprobe remains undissociated in the cell medium, and is amenable to facile derivatisation. Examination of data for seven Eu III and TbIII bimetallic helicates point to shortcomings in the phenomenological rules of thumb between the energy gap ΔE( 3ππ*-5DJ) and the sensitisation efficiency of the ligands.

Synthesis and antimalarial activity of 7-benzylamino-1-isoquinolinamines

(Chemical Equation Presented) Computer modelling suggests that 7-benzylamino-1-isoquinolinamines should mediate antimalarial effects by a mechanism distinct from that employed by existing antimalarial drugs. A series of these compounds was prepared in sev

Integrin expression inhibitors

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR4bR5b)mb— (wherein R4b and R5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mb means an integer of 1 or 2); R1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.